Clinical Trials
2 trialsNCT04819399 2022-04-05
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC
Lindis Biotech GmbH
Phase 1 Unknown
NCT01320020 2013-07-02
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
Phase 1 Terminated